Mar 26, 02:55 PM

Chemours Faces SEC, DOJ Probe Over Accounting Practices, Execs on Leave

Gene therapy maker bluebird will restate financials due to accounting errors. Chemours reports narrowed 4Q loss after investigation delay. SEC and DOJ probe Chemours over accounting practices, top executives on leave. Chemours discloses financial revisions post internal review. Chemours stock plunges despite earnings beat, facing net loss in 2023 amid litigation charges.

#Chemours #SEC #DOJ

Written with ChatGPT (GPT-3).

Sources

Open Outcrier@OpenOutcrier
2 years ago
$CC (-8.9% pre) The Chemours Co (CC) Faces Net Loss in 2023 Amidst Litigation Charges - Y Finance https://t.co/LO6fsKZ8Ws
Barron's@barronsonline
2 years ago
Chemours Stock Is Plunging Despite Earnings Beat. There Are Two Reasons. https://t.co/IM3MEdAFVW
Reuters Business@ReutersBiz
2 years ago
Chemours reveals certain financial revisions after internal review https://t.co/iKDZ5Xweu8 https://t.co/eb460sVcCy

Additional media

Image #1 for story chemours-faces-sec-doj-probe-over-accounting-practices-execs

Chemours Faces SEC, DOJ Probe Over Accounting Practices, Execs on Leave

Sources

Additional media

Similar Stories